Thank you for the opportunity to clarify that.
I would separate quite clearly clinical development and research from choosing vaccines to buy for Canada. We do here at the Canadian Center for Vaccinology at Dalhousie a number of very early vaccine studies. Most of those never make it forward to be manufactured or scaled up or used. It's very early clinical research, and that was the relationship with this adenovector virus vaccine platform that CanSino had. We were to do the phase one trial. We were all ready to do that and to enrol people and were just waiting for the arrival of the vaccine.
That's quite different from the task force as a whole, considering it as a potential candidate that might make it through the whole clinical development program to be a safe and effective vaccine.